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Aim: Propose a nanoparticle for neuron-targeted retrograde gene delivery and describe a 
microfluidic-based culture system to provide insight into vector performance and safety. Methods: 
Using compartmentalized neuron cultures we dissected nanoparticle bioactivity upon delivery taking 
advantage of (quantitative) bioimaging tools. Results: Targeted and nontargeted nanoparticles were 
internalized at axon terminals and retrogradely transported to cell bodies at similar average velocities 
but the former have shown an axonal flux 2.7-times superior to nontargeted nanoparticles, 
suggesting an improved cargo-transportation efficiency. The peripheral administration of 
nanoparticles to axon terminals is nontoxic as compared with their direct administration to the cell 
body or whole neuron. Conclusion: A neuron-targeted nanoparticle system was put forward. 




The stunning advances of nanotechnology over the past decades have boosted the engineering of 
biocompatible and biodegradable nanoparticles, allowing their application in the context of human 
diseases as novel vectors of therapeutic agents. In accordance with the desired purpose, the 
biophysicochemical properties of nanoparticles such as size, shape, surface charge and surface 
chemistry can be engineered to tune features that include stability at physiological conditions, 
encapsulation efficiency and release of therapeutic agents in a controlled manner over time, as well 
as cellular targeting and uptake efficiency[1]. 
One area in which the application of nanoparticles is becoming increasingly attractive and may have 
a significant clinical impact is the neuroscience field. In this context, nanoparticles can be used to 
mediate the delivery of bioactive molecules within the nervous tissue offering the possibility to reat 
diseases of the PNS and CNS. In what regards the use of nanoparticles to transfer such bioactive 
molecules to peripheral neu-rons some distinctive challenges arise. Peripheral neurons are widely 
distributed through-out the body, with long axons projecting peripherally to the target organs and 
centrally to the spinal cord. However, their cell bodies are located at the dorsal root ganglia (DRG) or 
at the spinal cord ventral horn, being relatively inaccessible to direct injection. Besides direct injection 
(intra ganglionic or intra-spinal) peripheral neuron cell bodies could be reached through intrathecal 
delivery or through the peripheral administration in the target tissues. From these, the latter prevails 
as a more clinically relevant route of administration due to its inherent low invasiveness. Thus, in this 
perspective, a suitable nanoparticle to mediate the delivery of molecules to peripheral neurons upon 
a peripheral tissue injection should possess the ability to bind specifically to neuron terminals and 
reach the desired neuron cell bodies by axonal retrograde transport. 
Despite the importance of axonal retrograde trans-port for the transference of mitochondria, 
autophagosomes, lysosomes and growth factors and their receptors to the neuron cell body, it has 
been demonstrated that the axonal retrograde transport route is also used as the main gateway for 
the entry and spread of exogenous materials into the nervous system, such as viral agents and 
neurotoxins (e.g., botulinum or tetanus neurotoxins [TeNT]) [2]. Similarly, nanoparticles can be 
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designed to mimic the entry of such pathogenic agents and gain access to the peripheral neuron cell 
bodies through their active retrograde axonal transfer. Thus, understanding how nanoparticles’ 
biophysicochemical properties relate to their uptake and retrograde transport along axons is an 
important step toward the developing of effective nano-based therapies.  
Due to the lack of resolution and sensitivity, in vivo imaging techniques (See [3] for an Editorial) do 
not allow the real-time tracking of nanoparticle-loaded vesicles in individual axons. Alternatively, the 
direct visualization of nanoparticle retrograde axonal trans-port and its quantitative analysis have 
been evaluated in in vitro neuronal cultures[4, 5], but the use of conventional cultures, where the 
nanoparticles are placed in contact with the whole neuron, hampers the out-come translation to in 
vivo conditions. Under these conditions, neurons can uptake nanoparticles along all cell plasma 
membrane (cell body, neurites, axons and axon terminals), and the anterograde and retrograde 
nanoparticle trafficking processes can occur simultaneously. A reliable in vitro assay for live imaging 
evaluation of nanoparticle retrograde axonal trans-port should recapitulate the desired in vivo 
peripheral route of administration in target tissues, in which nanoparticles only contact the neuron 
axon terminals. The recent introduction of microfluidic chambers as a tool in the context of neuronal 
cultures has allowed the establishment of compartmentalized cultures where neuron cell bodies and 
axonal terminals are physically separated. These microfluidic chambers are com-posed of two or 
more compartments interconnected by microgrooves that assure the separation of cell bodies from 
axonal terminals, thus, allowing precise spatial control of experimental conditions where axonal 
terminals and cell bodies can be subjected to selective treatments. The use of such microfluidic 
systems has been increasingly applied to neurosciences namely to study neuron/nonneuronal cells or 
tissue interactions [6, 7], axonal growth[8, 9], axonal mRNA transcripts [10], axonal motor proteins 
[11], axonal transport of neuro-trophins like NGF [12] and BDNF [13], tau proteins [14], neurotoxins 
[15], virus [16, 17] and mitochondria [18]. 
In this study we explore the use of a microfluidic-based DRG neuron culture to test the uptake and 
transport kinetics of gene carrying trimethylated chitosan (TMC)-based nanoparticles actively 
targeted to neurons by surface functionalization with the non-toxic and neurotropic C-terminal 54 
kDa fragment of the TeNT heavy chain (HC) [19], while mimicking a peripheral in vivo route of 
administration. This approach proved to be suitable to confirm, supported by real-time nanoparticle-
loaded vesicle visualization and quantification, the active retrograde transport of nanoparticles. To 
the best of our knowledge, this is the first report showing the applicability of such in vitro microfluidic-
based platforms as a model to simulate a peripheral route of administration for neurotropic 
nanoparticles and evaluate their uptake, retrograde axonal transport and toxicity profile in peripheral 
nervous system neurons. 
Materials & methods 
Preparation of microfluidic chambers for primary neuronal 
cultures 
The microfluidic chambers were prepared by placing the microfluidic devices (AXIS450, Millipore, 
France) against a glass coverslip. Briefly, sterile square glass coverslips (24 × 24 mm, Microscopic 
Glass Factory [MGF]-slides, Immuno-Cell, Belgium) were coated with 0.01 mg/ml of poly(D-lysine) 
(PDL, MW 30–70 kDa, Sigma-Aldrich Co., MO, USA) overnight at 37°C, washed with Milli-Q® water 
(Millipore) and completely air-dried under sterile conditions. Microfluidic devices were sterilized with 
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70% ethanol for 5 min as indicated by the manufacturer. After completely air-dried microfluidic 
devices were gently attached to PDL-coated glass coverslips, creating a microfluidic chamber 
composed of two compartments separated from each other by 450 μm length × 5 μm height × 10 μm 
width microgrooves. The medium reservoirs were loaded with 150 μl of 5 μg/ml laminin-1 isolated 
from mouse Engelbreth-Holm-Swarm sarcoma (Sigma-Aldrich Co.) and incubated overnight at 37°C. 
The unbounded laminin-1 was removed and chambers were washed once with DMEM with 
GlutaMAX™ (Gibco®, Thermo Fisher Scientific, MA, USA) refilled with DMEM medium and let to 
equilibrate for at least 2 h at 37°C, prior to cell seeding. 
Primary cultures of DRG neurons 
All experiments using animals were carried out with the permission of the local animal ethical 
committee in accordance with the EU Directive (2010/63/EU) and Portuguese law (DL 113/2013). The 
experimental protocol (reference 421/000/000/2013) was approved by the ethics committee of the 
Portuguese official authority on animal welfare and experimentation (Direção-Geral de Alimentação 
e Veterinária).Primary embryonic rat DRG neurons were isolated from Wistar embryo rats (E18). 
Briefly, rat embryos were dissected in Hank’s buffer solution (Sigma-Aldrich Co.) and enzymatically 
treated with 1.25% (w/v) collagenase type II (Gibco, Thermo Fisher Scientific) at 37°C for 90 min. 
Subsequently, collagenase was removed and DRGs washed three-times in DMEM followed by 
sequential mechanical dissociation with 1000 and 200 μl pipette tips. Viable cells were counted using 
the trypan blue (0.4% [w/v], Sigma-Aldrich Co.) exclusion assay and seeded at a density of 1 × 107 
viable cells/ml. For the microfluidic-based cultures, 5 μl of the cell suspension was pipetted to the cell 
body compartment (Figure 1A). For conventional cultures, 5 × 104 cells/cm2 were seeded in 48-well 
plates (for internalization assay) on glass cover-slips (10 mm, MGF-slides) or 1.56 × 105 cells/cm2 were 
seeded in 96-well plates (for metabolic activity assay), both previously treated with 0.01 mg/ml PDL 
as described above. Cells were allowed to attach for 1 h at 37°C. Subsequently, complete neuron 
culture medium constituted by DMEM/Ham’s F12 with GlutaMAX (DMEM/F12), 50 μg/ml of penicillin 
and streptomycin, 25 ug/ml fungizone, 2% (v/v) B27 supplement (all from Gibco, Thermo Fisher 
Scientific) and 50 ng/ml of NGF 7S (Calbiochem®, Millipore) was added to each cell culture platform. 
The culture medium was replaced every third day and cultures were kept in a humidified incubator at 
37°C supplied with 5% CO2. This DRG neuron isolation protocol resulted in 72% of neuron purity at 
48 h postseeding, determined by the percentage of neurons (immunostained for βIII tubulin, a 
neuron-specific microtubule marker using the monoclonal antibody mouse anti-βIII tubulin [1:1,000; 
Promega, WI, USA]) in relation to the total number of cells in culture (identified by nuclei staining 
with 0.1 μg/ml 4′,6-diamidino-2-phenylindole, Sigma-Aldrich Co.). 
Preparation of rhodamine-labeled TMC-based nanoparticles 
Synthesis of partially thiolated TMC 
TMC derived from ultrapure chitosan produced from Agaricus bisporus mushrooms, under current 
Good Manufacturing Practice standards, (40 kDa, KitoZyme, Belgium) was purified by filtration and 
dialysis prior to use, as described previously [20]. In brief, TMC was diluted in 5 mM HCl solution at a 
final concentration of 0.5% (w/v), filtered through a Buchner funnel and purified by dialysis using a 
3.5 kDa MW cut-off membrane (Spectrum Labs, CA, USA) for 3 days against deionized water and 
collected after freeze-drying. The degree of acetylation and quaternization of the purified TMC was 
characterized by 1H-nuclear magnetic resonance spectroscopy and determined to be 15.7 ± 0.9% and 
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30.1 ± 4.6%, respectively. Endotoxin levels of the purified polymer extracts were assessed using the 
Limulus Amebocyte Lysate Assay (QCL-1000, Cambrex, NJ, USA), following the manufacturer 
instructions. Endotoxin levels were found to be <0.1 EU ml/1 (an EU correspond-ing to a unit of 
measurement for endotoxin activity), respecting the US Department of Health and Human Services 
guidelines for implantable devices [21]. After freeze-dried, TMC was dissolved in 20 mM HEPES 
(Sigma-Aldrich Co)-buffered saline solution containing 5% (w/v) glucose (pH 7.4) at a 0.25% (w/v) final 
concentration. Purified TMC was then partially thiolated by the immobilization of thiol groups from 
2-iminothiolane on the primary amino groups of the polymer, as described elsewhere [22]. Briefly, 
TMC was dissolved in 20 mM HEPES buffer at 5 mg/ml and 2-iminothiolane hydrochloride (Sigma-
Aldrich Co.) was added to the polymer solution, in order to attain a theoretical modification of 10% 
of the polymer primary amine groups. Afterward, the pH of the solution was adjusted to 8 with NaOH. 
After 6 h of incubation at room temperature (RT), under an inert atmosphere saturated with argon 
and with continuous stirring, the resulting thiolated TMC (TMCSH) was dialyzed for 3 days against 5 
mM HCl at 4°C. Thereafter, samples were frozen at -80°C and lyophilized for 3 days. The resulting 
powders were stored at -20°C until further use. 
To allow the tracking of TMCSH-based nanoparticles, the polymer was fluorescently labeled with the 
rhodamine-activated derivative 5(6)-carboxy-X-rhodamine N-succinimidyl ester (ROX) (Sigma-
Aldrich Co.). The rhodamine reagent was dissolved in methanol to attain a final ratio of 1:1 
H2O:methanol. For TMCSHROX modification, the ROX solution was added to the TMC-iminothiolane 
hydrochloride reaction, after 3 h of incubation, in a NH2:ROX ratio of 7.4:1. The reaction was then 
incubated for an additional period of 3 h, in an inert atmosphere at RT and under continuous stirring. 
The resulting polymer conjugate was then purified as described above. 
Determination of polymer thiol content 
The degree of polymer thiolation was quantified with 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB, 
Ellman’s reagent). The amount of free thiol groups grafted to the polymer was determined based in 
a pre-viously described protocol [19] and found to be 149.1 ± 15.8 μmol/g, corresponding to 4.7 ± 0.5% 
substitution of TMC primary amines by thiol groups. Briefly, 
DTNB was dissolved in 0.1 M sodium phosphate buf-fer, pH 8 at a final concentration of 100 μg/ml. 
The polymer samples were dissolved in the same solution at a final concentration of 2.5 mg/ml. Then, 
20 μl of the polymer solution was mixed with 180 μl of DTNB reagent solution in a microplate and 
after incubation of 15 min at RT the absorbance was measured at a wave-length of 405 nm (Spectra 
Max GeminiXS, Molecu-lar Devices, CA, USA). Cysteine standards were used to calculate the amount 
of free thiol moieties in the polymer. 
Plasmid DNA production & purification 
The plasmid DNA (pDNA) used encoded for the TdTomato protein (pCSCMV:tdTomato, 5.5 kb, Add-
gene, UK) and was produced in DH5α competent Escherichia coli strain and purified using a EndoFree 
plasmid Giga kit (Qiagen, Germany) following the manufacturer’s instructions. Plasmid 
concentration and purity were assessed by UV spectroscopy (Nano-drop ND-1000, Thermo Fisher 
Scientific) and the absorbance ratio achieved (260/280 nm) was between 1.8 and 2.0. 
HC fragment production, purification & modification 
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The plasmid encoding for HC fragment was a kind offer from Neil Fairweather (King’s College, UK). 
The pro-duction using transformed BL21 Escherichia coli strain and purification of HC fragment was 
performed as pre-viously described[19]. The purified fragment was then modified with a bifunctional 
5 kDa PEG spacer (JenKem Technology, China) bearing an N-hydroxysuccinimide and a maleimide 
end group, at a 2.5 PEG/HC protein molar ratio. The amount of reactive maleimide groups in the HC 
fragment was determined using a modified Ellman’s assay [23] and found to be 1.5 mol PEG/HC 
Nanoparticle preparation 
TMCSH-based nanoparticles were prepared using an N/P molar ratio (moles of quaternized amine 
groups [N] to moles of DNA phosphate groups [P]) of 8. Briefly, the nanoparticle core was formed by 
mixing, while vortexing, equal volumes of plasmid DNA solu-tion with TMCSH solution in 20 mM 
HEPES-buff-ered saline solution containing 5% (w/v) glucose, pH 7.4. Complexes were let to stabilize 
for 15 min at RT and then the pegylated HC fragment (HC-PEG) was added to the nanoparticle 
solution in a w/w ratio of HC-PEG per pDNA of 4, and let to react for 24 h under agitation, at RT. 
Rhodamine labeling of HC fragment 
HC fragment alone was used as a control in the cellular uptake studies. To allow the tracking of HC 
fragment it was fluorescently labeled with ROX. In brief, 0.4 ml of rhodamine solution (2.5 mg/ml in 
dehydrated dimethylformamide) was added in drop wise to 6 mg of purified HC protein at 1 mg/ml in 
0.1 M phosphate buffer (pH 5.5) and let to react for 1 h, at RT, under constant stirring and protected 
from light. The purified rhodamine-labeled HC fragment (HCROX) was washed several times with 0.1 
M phosphate buffer and concentrated using a 30 kDa cut-off filter (Amicon Ultra, Mil-lipore). 
Subsequently, HCROX solution was filtered and stored at -20°C until further use. Characterization of 
TMCSH-based nanoparticlesTMCSH-based nanoparticles grafted or not with HC-PEG were 
characterized in terms of size, polydispersity index (Pdi) and ζ potential using a Zetasizer Nano Zs 
(Malvern, UK). The Smoluchowski model was applied for ζ potential determination and cumulants 
analysis was used for Z-average particle size determination. Ten micrograms of pDNA were used to 
prepare the tested formulations. All measurements were performed in triplicate, at 25°C. 
Cellular uptake of TMC-based nanoparticles 
To evaluate the cellular interaction and uptake of non-targeted TMCSHROX and neurotropic 
TMCSHROX-HC nanoparticles we performed an internalization assay using the microfluidic and 
conventional-dissociated DRG neuron cultures. The HCROX fragment was used as control. For 
microfluidic-based cultures HCROX or nanoparticles were supplied in the medium of the axonal 
compartment while for conventional cultures a similar amount of HCROX or nanoparticles were 
provided to the whole culture in the culture medium (Figure 1B & C, respectively). Particular care was 
taken in the microfluidic-based cultures to assure that the media volume at the cell body 
compartment was at all times higher than the media volume at the axonal compartment. This small 
hydrostatic pressure difference resulted in a slow but continuous flow of medium across the 
microgrooves from the somal side to the axonal side, preventing the free passage of HC protein or 
nanoparticles to the cell body compartment. Following an incubation of 5 or 12 h, at 37°C, unbounded 
HCROX protein or nanoparticles were washed two-times with phosphate-buffered saline and cells 
were fixed with 4% (w/v) paraformaldehyde. To discriminate neurons from the nonneuronal cells 
present in culture, fixed cells were stained as previously described. 
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Microfluidic live imaging & analysis Nanoparticle transport 
Live imaging was performed at 37°C using a laser scanning confocal microscope Leica TCS SP5 II 
(Leica Microsystems, Germany) with the HC PL APO CS 40× /1.10 water or HC PL APO Lbl. Blue 
63×/1.40 oil objectives. Laser line at 561 nm was used for rhodamine excitation. For each treatment 
group, a total of 24 microgrooves (containing at least one axon) were randomly selected for live 
imaging. The microgrooves were imaged in the proximity of the cell body compartment, 1 h following 
TMC-based nanoparticles application in the axonal compartment. All image series were acquired for 
3–5 min, 4 s/frame. This interval of seconds between frames allowed for long-term imaging without 
dye bleaching. Images were acquired from three independent experiments. For the tracking and 
analysis of nanoparticle-loaded vesicles (TMCSHROX positive vesicles), 12 images series for each 
condition were selected. Images series were analyzed using a custom-made program written in 
MATLAB (The MathWorks, version 2015a, MA, USA). The program provided tools for semiautomatic 
and manual tracking of the vesicles, and a tool for the calculation of the flux of vesicles in the axons. 
For tracking, image series were preprocessed with a Laplacian of Gaussian filter scaled according to 
the median size of the nanoparticle-loaded vesicles. This provided an enhancement of blob-like 
structures in the image and, as a consequence, an increase in contrast between vesicles and 
background. Segmentation was performed through a user-defined intensity threshold. The center of 
each vesicle was calculated as the centroid in the intensity profile. Semiautomated tracking was 
performed whenever possible – in these cases the user selected the seed locations of vesicles and a 
detection-association algorithm, based on near-est neighbor detections between consecutive 
frames, automatically followed the vesicles trajectories. The trajectories were reconstructed 
manually in situations where the vesicles contrast was low or the vesicles positional changes between 
frames were large enough to impair the detection-association algorithm (meaning that 
semiautomated tracking was not feasible). For the analysis, only moving vesicles tracked over at least 
four consecutive frames within a sequence of frames were considered. Vesicles that moved further 
than 10 μm were classified as a run. Any movement <10 μm (between two pauses or between the 
beginning or end of the sequence and a pause) was not considered as a run and was integrated into 
the adjacent pause period. A pause was determined as a sequence of frames during which the vesicles 
moved below the instantaneous speed of 0.1 μm/s in each frame, with a minimum duration of 8 s. 
The instantaneous velocity was determined by the ratio between the distance (μm) and the time (s) 
covered by a vesicle in two consecutive frames. Using these criteria, the probability density function 
of nanoparticle-loaded vesicle instantaneous velocity, the average velocity of each vesicle, the length 
of each run and the duration of each pause were quantified. 
The axonal flux of nanoparticle-loaded vesicles in the retrograde direction was quantified based on 
the velocity and density of vesicles (number and size of vesicles) passing through the axon’s cross-
section. It is presented as the number/density of particles per unit of length (the axon’s cross section) 
per unit of time. To estimate the flux of nanoparticles in the image series, it was assumed that the 
amount of nanoparticles in a vesicle is proportional to the total intensity level (fluorescence) of the 
area occupied by the vesicle (in the image). Furthermore, flux for a specific experimental condition 
was estimated in terms of mean values: the mean vesicle density was multiplied by the mean vesicles 
velocity to give the mean flux for the specific experimental condition. Mean vesicle density was 
calculated by image analysis in a sequence of steps. First, image series were preprocessed cropping 
the images to the microgroove interior area and performing noise reduction using a Gaussian filter 
with a spatial scale smaller than the average vesicle size. Segmentation was then performed and the 
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background was zeroed. The sum of all positive pixels was then taken from the difference between 
consecutive frames. This operation allowed for the selective integration of intensities associated with 
moving structures. The vesicle density, for each pair of images, was given by this sum, normalized by 
the total area of the image (cropped to the microgroove borders). Mean values and standard 
deviations were obtained from the full sequence in the image series. Mean vesicles velocity was 
calculated from the tracking of the vesicles trajectory. The velocity of each vesicle was calculated 
performing a linear regression on the axonal axial position as a function of time. 
Mitochondria motility assessment after nanoparticle treatment 
The axonal transport of mitochondria was analyzed by confocal live imaging to determine if 
nanoparticle treatment impacts the overall mitochondria motility. Briefly, mitochondria of DRG 
neurons cultured in microfluidic chambers were labeled with 200 nM Mitotracker® Green FM 
(Molecular Probes,Thermo Fisher Scientific) for 20 min at 37°C. Afterward, cells were washed once 
with medium and kept in a humidi-fied incubator overnight, at 37°C supplied with 5% CO2. 
Nanoparticles were then supplied in the axonal compartment and incubated with axon terminals for 
1 h at 37°C. Subsequently, axons within microgrooves were live imaged using a laser scanning 
confocal microscope Leica TCS SP5 II (Leica Microsystems, Germany) with the HC PL APO Lbl. Blue 
63×/1.40 oil objective. Laser line at 488 nm was used for Alexa Fluor® 488 excitation (Thermo Fisher 
Scientific). For each treatment group, a total of 12 microgrooves (containing at least one axon) were 
randomly selected for mitochondria tracking. All image series were acquired for 3 min, 1 s/frame. 
Images were acquired from three independent experiments. Images series were analyzed using a 
custom-made program written in MATLAB. For each condition, imaged mitochondria were 
characterized into moving or paused/stationary mitochondria. The average velocity (μm/s) of moving 
mitochondria, either showing retrograde, anterograde or bidirectional movement, was additionally 
determined for each treatment condition. 
Intracellular vesicle labeling 
DRG neurons treated with both nanoparticle for-mulations were immunostained for the clathrin and 
caveolin-1 proteins, structural components of the intracellular vesicles, to check for co-localization 
with nanoparticles. In brief, after 1 h of nanoparticles incubation into the axonal compartment of 
microfluidic cultures, unbounded rhodamine-labeled nanoparticles were washed two-times with 
phosphate-buffered saline and cells were fixed with 4% (w/v) paraformaldehyde. Afterward, clathrin- 
and caveolin-1-associated vesicles were immunostained using a monoclonal anti-body rabbit anti-
clathrin (1:50; Cell Signaling Technology, MA, USA) or a monoclonal antibody rabbit anti-caveolin-1 
(1:200; Cell Signaling Technology). A polyclonal goat anti-rabbit Alexa Fluor 488 conjugated (1:500; 
Molecular Probes™, Thermo Fisher Scientific) was used as secondary antibody. 
Neuronal metabolic activity assay 
The neuronal metabolic activity was assessed, after incubation of both culture types with the 
nanoparticles, by measuring the adenosine 5′-triphosphate (ATP) levels. The nanoparticles vehicle 
(20 mM HEPES-buffered saline solution containing 5% (w/v) glucose [pH 7.4]), TMCSH or TMCSH-HC 
nanoparticles were added to the whole medium in conventional cultures or to the cell body or axonal 
compartment medium of microfluidic cultures, and let in contact for 6 or 12 h. Intracellular ATP levels 
were measured using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) with some 
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adaptations from the manufacturer’s protocol. In brief, cells in 96-well plate and microfluidic 
chambers were gently trypsinized, collected and washed with medium. The CellTiter-Glo® Reagent 
was added to the cells resulting in cell lysis and generation of a luminescent signal proportional to the 
amount of cellular ATP present in each condition. As recommended by the manufacturer, the 
luminescence was measured after 10 min of incubation in a luminescent plate reader (SYNERGY MX, 
BioTeK, France). ATP disodium salt hydrate (Sigma-Aldrich Co.) was used to prepare an ATP 
standard curve. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.0 for Windows (CA, USA). Unless 
mentioned otherwise, results are presented as mean ± standard deviation. The D’Agostino and 
Pearson omnibus normality test was used to test if data obeyed to a Gaussian distribution. To verify 
whether ROX-labeling interfered with the physicochemical properties of nanoparticles, the 
nonparametric Mann–Whitney U test was performed to compare each nanoparticle formulation 
before and after ROX labeling. To deter-mine whether differences existed between treatments 
regarding duration of pause periods and axonal flux, an unpaired t-test was used. As the average 
velocity of each vesicle and run length parameters did not follow a Gaussian distribution the 
nonparametric Mann–Whitney U test was performed to compare both treatment groups. To 
determine whether a difference in mitochondria axonal transport and ATP synthesis existed between 
nanoparticle treatment and control, in each culture condition, the one-way ANOVA test was 
performed followed by the Tukey’s post-test. Results with p < 0.05 were considered statistically 
significant. 
Results 
Nanoparticle physicochemical characterization 
Both nanoparticle formulations used in the present study – nontargeted TMCSHROX and neurotropic 
TMCSHROX-HC nanoparticles – were characterized at first in terms of size, Pdi and ζ potential. As 
illustrated in Table 1, the mean size diameter values obtained for TMCSHROX-HC nanoparticles is not 
significantly different from the naked nanoparticles showing that HC functionalization does not 
influence the average size of the nanoparticles. ζ potential values obtained for both nanoparticles 
were positive and not significantly different, indicating a cationic surface charge of nanoparticles with 
a good colloidal stability, independent of HC functionalization. Moreover, it was confirmed that the 
size and ζ potential values of ROX-labeled nanoparticles were not significantly different from their 
unlabeled counterparts (Supplementary Table 1) indicating that the nanoparticle-labeling procedure 
does not influence their main physicochemical properties. 
Cellular uptake of TMC-based nanoparticles 
Dissociated DRG neuron cultures were incubated with nanoparticles for 5 or 12 h, at 37°C. In 
conventional DRG neuron cultures, HCROX or nanoparticles were supplied in the culture medium to 
the whole culture (Figure 1C), while in microfluidic-based cultures these were supplied only in the 
culture medium of the axonal compartment (Figure 1B). Confocal microscopy analysis demonstrated 
a widespread cellular internalization of HCROX, TMCSHROX and TMCSHROX-HC in conventional cultures 
(Figure 2 for 5 h and Supplementary Figure 1 for 12 h of incubation), regard-less of the incubation 
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period or cellular type. Furthermore, a direct relation between incubation time and cellular 
internalization extent was not observed. In microfluidic DRG neuron cultures, HCROX and both 
nanoparticle formulations were highly associated with axonal terminals in the axonal compartment 
(Figure 3G, H & I) and were found in some neurons at the cell body compartment, although in 
different quantities concerning each treatment condition and time of incubation. After 5 h of 
incubation, HCROX was detected within the cell body of neurons that exclusively lay in the cell body 
compartment of the microfluidic chambers, enclosed in small round shape structures, suggesting it 
has been condensed in intra-cellular vesicles that were found distributed the cytoplasm (Figure 3A). 
Contrarily, TMCSHROX-HC nanoparticles, although also detected at the micro-fluidic cell body 
compartment, were only detected in few axonal processes (Figure 3C), while evidence of TMCSHROX 
nanoparticles in this compartment was not noticeable at this time point of analysis. The increase in 
incubation time resulted in a higher accumulation of HCROX in the neuron cell bodies that was 
detected in vesicles predominantly located at the nuclei periphery (Figure 3D). Similarly, after 12 h of 
incubation, TMCSHROX and TMCSHROX-HC nanoparticles were detected in neuron cell bodies in small 
round vesicular structures, being the amount of TMCSHROX-HC nanoparticle-loaded vesicles higher 
than the ones carrying the TMCSHROX nanoparticles (Figure 3E & F, respectively). 
Another important finding observed in microfluidic DRG neuron cultures was the fact that HCROX or 
nanoparticles were not detected in all neuron cell bodies neither in any of the non-neuronal cells 
present at the cell body compartment, confirming that only the neurons that had grown their axons 
to the axonal compartment were able to internalize and transport the HCROX or nanoparticles to their 
cell bodies. 
TMCSH-based nanoparticles retrograde axonal transport 
To explore the ability of TMCSH-based nanoparticles to be retrogradely transported from axonal 
terminals to the neuron cell bodies, live imaging was per-formed using the microfluidic DRG neuron 
cultures. Nanoparticles were supplied to the medium in the axonal compartment and axons inside 
microgrooves were subsequently imaged in the proximity of the cell body compartment. 
Live imaging analysis showed several nanoparticle-loaded vesicles being retrogradely transported in 
axons after internalization in their terminals at the axonal compartment (Figure 4 & Supplementary 
Videos 1 & 2). TMCSHROX-HC nanoparticle-loaded vesicles were observed in retrograde axonal transit 
in all axons imaged. Contrarily, not all axons imaged for TMCSHROX nanoparticles showed the 
transport of nanoparticle-loaded vesicles (only 75%), and the total amount of transported 
nanoparticles in each axon appears to be lower than the one observed for TMCSHROX-HC 
nanoparticles (Supplementary Videos 1 & 2). Immunostaining of vesicles being transported along the 
observed axons revealed several co-localization events of both nanoparticle formulations with 
clathrin and caveolin-1-associated vesicles, although these were more frequent for clathrin than 
caveolin-1-positive structures in the case of TMCSHROX-HC (Supplementary Figure 2). 
By monitoring and tracking the nanoparticle trafficking along the axons, the motion properties of 
loaded vesicles with both nanoparticle types were characterized using a number of parameters, 
namely the probability density function of the instantaneous velocity, the average velocity, the time 
spent in movement versus pause and the axonal flux. The probability density function of 
instantaneous velocity showed more variability and higher median instantaneous velocity for 
TMCSHROX-loaded vesicles as compared with the peaked TMCSHROX-HC-loaded vesicles velocity 
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distribution (Figure 5A). Also, vesicles carrying TMCSHROX nanoparticles showed more anterograde 
movements (depicted by negative values of the instantaneous velocity) that represented short 
reversals in direction for vesicles that were moving in the net retro-grade direction. However, when 
looking into the aver-age velocity values, vesicles loaded with TMCSHROX or TMCSHROX-HC 
nanoparticles were transported both at high velocities (>1 μm/s), in the range of fast axonal transport 
(Figure 5B), made long runs with similar total distances progressed (Figure 5C) and spent similar 
pause time periods during a run (Figure 5D). Nevertheless, the axonal flux of nanoparticle-loaded 
vesicles in axonal transit was significantly higher for the ones carrying the TMCSHROX-HC 
nanoparticles (Figure 5F). As described before, the physical quantity flux takes concurrently into 
consideration the density of vesicles (number and size of vesicles) and their velocity (Figure 5E). This 
assessment is relevant as axons with nanoparticle-loaded vesicles travelling all at the same velocity 
may present distinct fluxes if the density of vesicles is different (either due to the fact that the vesicles 
have distinct sizes, or are present in different numbers, as illustrated in Figure 5E axons A and B). 
Conversely, axons can present similar fluxes, even when the transported vesicles are present in 
similar densities, when the vesicles are being transported at different average velocities (Figure 5E – 
axon A and C). 
Mitochondria axonal transport 
To determine if nanoparticle treatment modifies the normal axonal transport in neurons we 
evaluated and compared the axonal transport of mitochondria between control (untreated) and 
nanoparticle-treated neuron cultures (after 1 h of contact with the nanoparticle formulations) 
(Supplementary Videos 3–5). Our results show that the majority of axonal mitochondria remain 
paused/stationary during the acquisition time (approximately 80%), both in control and nanoparticle-
treated neurons (Figure 6A). Moreover, in all groups in study the moving mitochondria presented a 
similar average transport velocity (Figure 6B). 
Neuronal metabolic activity 
To compare the impact of nanoparticle administration to the whole cell versus to the axonal terminals 
(as occurs in an in vivo peripheral administration in target tissues), we assessed the cellular metabolic 
activity by measuring the intracellular ATP levels after 6 and 12 h of nanoparticle incubation in 
conventional and micro-fluidic cultures, respectively. To discard any interference that could result 
from the use of different cell culture conditions (conventional versus microfluidic), we also compared 
the impact of nanoparticle administration directly to the cell bodies versus the axonal terminals in a 
microfluidic setup. Cells cultured in conventional platforms demonstrated a sharp decrease in their 
intra-cellular ATP levels for both nanoparticle formulations, compared with untreated cells (Figure 
7). Conversely, cells cultured in microfluidic chambers and treated with nanoparticles in the axonal 
compartment, either maintained their intracellular ATP levels similar to the control (Figure 7) or 
presented a significant increase in their intracellular ATP levels as observed at 6 h post-treatment 
with the TMCSH nanoparticles ( Figure 7A). Additionally, cells cultured in microfluidic chambers and 
treated with nanoparticles in the cell body versus the axonal compartment showed a similar behavior, 
with significantly reduced ATP levels being observed when nanoparticles were administrated directly 
to the cell bodies (Figure 7C & D). 
Discussion 
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Aiming at developing new therapeutic strategies to treat nervous system diseases, researchers have 
been exploring the development of targeted nanoparticles to mediate the delivery of therapeutic 
molecules to specific neuron populations, as well as clinical relevant routes for heir administration in 
the body. Our research group is particularly interested in the development of biocompatible and 
biodegradable nanoparticles to mediate the targeted delivery of therapeutic genes to DRG neurons 
upon their peripheral and minimally invasive administration in target tissues. This route of 
administration requires that the selected nanoparticles have to be internalized at the axon terminals 
and be retrogradely transported to the neuron cell body. To attain nanoparticle neurotropism we are 
exploring the tethering of the nanoparticles’ surface with a pegylated HC fragment, as previously 
reported[19], since this nontoxic fragment of the TeNT is described to be neurotropic and capable of 
being retrogradely transported along peripheral neu-rons[24, 25]. Nevertheless, the assessment of 
retrograde axonal transport ability of these nanoparticles has been hampered by the limited imaging 
resolution and sensitivity inherent to currently available in vivo real-time imaging techniques, as well 
as the inefficacy of conventional in vitro neuronal cultures to mimic a peripheral in vivo administration 
for these nanoparticles. These shortcomings motivated us to establish an in vitro plat-form that can 
recapitulate an in vivo peripheral route of nanoparticle administration by using a microfluidic 
chamber to culture dissociated DRG neurons. 
The use of microfluidic chambers offers technical advantages over conventional cultures. The 
embedded microgrooves in the microfluidic chamber allow axons to grow through it and to be 
efficiently isolated in the axonal compartment. Moreover, in such platforms one can restrict 
nanoparticle internalization to occur only at axon terminals, which is not possible to control in 
conventional cultures. Furthermore, in this manner, a large number of axons can be analyzed in a 
given chamber allowing the axonal transport evaluation and quantification. Our results on the study 
of cellular uptake of nanoparticles corroborate the advantage of using microfluidic neuron cultures 
over conventional ones. DRG neuron conventional cultures incubated with the two-tested 
nanoparticle formulations (targeted versus nontargeted) resulted in a broad cellular nanoparticle 
uptake, despite cellular type and nanoparticle formulation. In opposition, using microfluidic DRG 
neuron cultures, different nanoparticle accumulation rates in the neuron cell body were observed for 
the TMCSHROX and TMCSHROX-HC formulations, suggesting a different uptake mechanism for each 
nanoparticle type. These findings highlight the limited utility of conventional cultures to discriminate 
such differences for nanoparticles with distinct surface functionalization. 
Furthermore, in these microfluidic platforms, one was able to explore, using confocal live cell 
imaging, the uptake and axonal transport kinetics of TMC-SHROX and TMCSHROX-HC nanoparticles 
upon their contact with axonal terminals. Both nanoparticle formulations were found to be 
transported with similar average velocities, in the range of fast axonal transport [26, 27]. This 
observation suggests that nanoparticle surface functionalization with the HC fragment does not 
influence the retrograde axonal transport average velocity of these nanoparticles. Rather, both 
naked and HC-functionalized nanoparticles may be transported in vesicles directed to the neuron cell 
body using the microtubule-dependent molecular motor dynein, the responsible for cargoes 
retrograde axonal transport [28]. However, our data for the probability density function of the 
instantaneous velocity showed a different distribution of the instantaneous velocities for vesicles 
carrying each nanoparticle formulation. TMCSHROX-HC nanoparticle-loaded vesicles showed a picked 
instantaneous velocity distribution ranging from 0.2 to 3.9 μm/s, similar to what has been described 
for retrograde axonal transport of HC fragment of TeNT in vitro[29, 30]. In contrast, TMCSHROX 
nanoparticle-loaded vesicles displayed a variable instantaneous velocity distribution and also some 
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movements in the anterograde direction. This change in TMCSHROX nanoparticle-loaded vesicles 
motility probably arises from changes in the number of motor proteins actively attached to these 
vesicles at a particular time that may be influenced by their cargo, as has been argued in previous 
studies [31, 32 
While the type of intracellular transport (passive versus active) involved in nanoparticle trafficking 
can be assessed based on velocity studies, the efficiency of a nanoparticle in targeting the soma is 
more accurately captured by the flux of loaded vesicles in the retrograde transport, as opposed to 
considering uniquely the velocity. Here the nanoparticle axonal flux was quantified taking into 
consideration the velocity as well as the density of vesicles (number and size) passing through an 
axon’s cross-section. Our results disclosed a higher axonal flux for vesicles carrying the TMCSHROX-
HC nanoparticles, evidencing a more efficient retrograde axonal transport of these vesicles as 
compared with the vesicles transporting the TMCSHROX nanoparticles. Taking into account that the 
average velocity of both nanoparticle formulations is similar, this difference can only be explained by 
a different density of vesicles in axonal transit for each condition that could be dependent on 
differences in vesicle number, size or both. 
Taken together, these observations suggest that the process of binding/internalization for each 
nanoparticle formulation is distinct and this may result in different efficiencies in the retrograde 
axonal transport associated with each nanoparticle formulation. We hypothesize that TMCSHROX-HC 
interact with axon plasma membrane mainly through TeNT receptor complex, constituted by 
polysialogangliosides and glycosylphosphatidylinositol-anchored proteins [33, 34], and are 
internalized as a consequence of membrane receptor activation in clathrin-mediated endosomes, as 
has been reported for HC [33]. Immunostaining of vesicles being transported along the observed 
axons revealed a higher occurrence of co-localization of TMCSHROX-HC nanoparticles and clathrin-
positive vesicles than caveolin-1-positive structures (Supplementary Figure 2). This receptor-
mediated internalization and transport hypothesis is in line with our previous observations with HC-
functionalized nanoparticles based either on poly(ethylene imine) [19, 35] or chitosan [36]. Once 
inside the cell, vesicles carrying TMCSHROX-HC nanoparticles interact with dynein/dynactin complex 
and are retrogradely transported to the cell body, with an average velocity similar to what has been 
reported to the fast retrograde axonal transport. In opposition, TMCSHROX nanoparticles interact 
with the axon plasma membrane through electrostatic interactions. Although TMCSHROX 
nanoparticles were found to co-localize with clathrin and caveolin-1-associated vesicles 
(Supplementary Figure 2), we believe that the inexistence of a targeting moiety in these 
nanoparticles favors a nonspecific internalization, possibly in nonclathrin and noncaveolae-mediated 
endosomes [37]. Previous reports have proven that sulfated proteoglycans present at the cellular 
plasma membrane contribute, together with phospholipids, to its negative net charge and can act as 
plasma membrane carriers [38] and mediate cellular internalization of cationic delivery systems [39, 
40]. This nonspecific internalization process in the context of the axonal terminals is probably not as 
efficient as the receptor-mediated uptake, which can explain the fact that not all axons imaged in the 
microfluidic chambers transported vesicles containing the TMC-SHROX nanoparticles. Nevertheless, 
upon internalization vesicles transporting the TMCSHROX nanoparticles that interact with the 
dynein/dynactin complex are retrogradely transported to the cell body as well. 
Since nanoparticle toxicity at the cellular level can translate into clinical toxicity, we took advantage 
of these microfluidic DRG neuron cultures to explore the impact of nanoparticle administration on 
neuron metabolic activity. Our results demonstrate that both nanoparticle formulations exerted a 
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marked drop in metabolic activity as compared with control when in contact with the cell body or 
whole cell (conventional cultures) rather than in contact with the axonal terminals. This can be related 
to higher interactions with cell membrane, internalization events and intracellular accumulation 
observed in cell body and conventional administration conditions. In opposition, the administration 
of nanoparticles solely in the proximity of the axonal terminals did not affect the cellular metabolic 
activity, being the ATP consumption levels equal to the control. Moreover, we show that nanoparticle 
treatment does not influence the mitochondria axonal transport, at least at this time point of 
analysis. It has been previously reported that mitochondria alter their motility under certain stress 
conditions or when their integrity is impaired [41]. Based on the above one can conclude that 
different nanoparticle routes of administration can trigger distinctive biological responses for the 
same nanoparticle formulation. This highlights the importance of conducting cytotoxicity studies in 
similar conditions to their desired route of administration in the body, in detriment of eliminating 
useful nanoparticle formulations. 
Conclusion 
Here we describe the use of a microfluidic-based DRG neuron culture to mimic in vitro an in vivo 
peripheral route of nanoparticle administration near axonal terminals (e.g. intramuscular delivery). 
Using this platform we were able to discriminate the trafficking properties of different nanoparticle 
formulations, such as the higher axonal flux of TMCSH-HC nanoparticles-loaded vesicles, otherwise 
not feasible using con-ventional DRG neuron cultures, inferring from the efficiency of the delivery 
process mediated by different nanoparticles. Moreover, this system showed to be of added value in 
the evaluation of nanoparticle-mediated cytotoxic effects, an issue that can be extended to other 
research areas to allow the study of other nanoparticle formulations safety. The application of this 
micro-fluidic-based platform provided experimental evidence for the retrograde axonal transport 
and safety of TMCSH-HC nanoparticles that can be applied to subsequent in vivo studies. Finally, this 
work further contributes to an emerging literature demonstrating the advantageous application of 
microfluidic devices for neuroscience-related research. 
Altogether our results show that this microfluidic-based neuron culture is a powerful tool to 
investigate nanoparticle bio-performance, namely, regarding cell–nanoparticle interactions, 
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Figure 1. Schematic representation of microfluidic-based and conventional dorsal root ganglia neuron 
cultures. (A) Illustration of cell seeding in the cell body compartment of microfluidic chambers. Neurons grow 
their axons to the axonal compartment in 3–4 days after seeding. (B) Side-view illustration of nanoparticle 
incubation in microfluidic or (C) conventional DRG neuron cultures. In microfluidic-based cultures, nanoparticles 
are supplied in the culture media in the axonal compartment while in conventional cultures nanoparticles are 
supplied in culture media to the whole culture. In microfluidic-based cultures, a difference in media volume was 
used to induce a small hydrostatic pressure variance and force the media flow across the microgrooves from the 
cell body compartment to the axonal compartment, avoiding the free passage of nanoparticles to the cell body 
compartment. 
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Figure 2. HC fragment and nanoparticle internalization in conventional dorsal root ganglia neuron cultures. 
Representative images of dorsal root ganglia neurons cultured in 48-well plates (conventional cell cultures) and 
incubated with rhodamine-labeled HC fragment, TMCSHROX or TMCSHROX-HC nanoparticles for 5 h. For neuronal 
cells identification, cells were immunostained for βIII tubulin, a neuron-specific microtubule marker (green), and 
nuclei were stained with DAPI (blue). Rhodamine-labeled HC fragment and nanoparticles are identified in red 
(arrows).  Scale bar: 25 μm.  
DAPI: 4′,6-diamidino-2-phenylindole; ROX: 5(6)-carboxy-X-rhodamine N-succinimidyl ester; TMCSH: Thiolated 
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Figure 3. HC fragment and nanoparticle internalization in microfluidic-based dorsal root ganglia neuron 
cultures.  Representative images of dorsal root ganglia neurons cultured in a microfluidic-based system and 
incubated with rhodamine-labeled HC fragment (A, D & G), TMCSHROX (B, E & H) or TMCSHROX-HC nanoparticles 
(C, F & I) for 5 h (A–C) or 12 h (D–F) in the axonal compartment. For neuronal cells identification, cells were 
immunostained for βIII tubulin, a neuron-specific microtubule marker (green), and nuclei were stained with DAPI 
(blue). Rhodaminelabeled HC fragment and nanoparticles are identified in red (arrows). Scale bar: 25 μm. 
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Figure 4. Retrograde axonal transport of thiolated trimethyl chitosan-based nanoparticles. (A) Application of 
nanoparticles to the axon terminals in the axonal compartment of microfluidic-based neuron cultures resulted 
in their retrograde axonal trafficking toward the cell body compartment. Scale bar: 5 μm. (B) Confocal image 
orthogonal views (XY, XZ, YZ) through one axon in a microgroove showing a nanoparticle-loaded vesicle (arrow; 
red) being trafficked inside the axon, immunostained for βIII tubulin (green). Dashed lines indicate the selected 
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Figure 5. Retrograde axonal transport analysis of thiolated trimethyl chitosan-based nanoparticles. (A) 
Probability density function of the instantaneous velocity frequency of TMCSHROX and TMCSHROX-HC-loaded 
vesicles, defined as the speed (μm/s) of movement between two sequential images during a run. Each value 
represents the velocity of a single step between two frames. Arrows indicate the median value for instantaneous 
velocity distribution of each nanoparticle population. (B) Representation of the average velocity (μm/s) of 
retrograde axonal transport of nanoparticle-loaded vesicles, (C) total run length progressed (μm) and (D) total 
pause periods (s). Values represent mean ± SD. (E) Illustration of longitudinal cross-section of three axons showing 
the retrograde transport of several vesicles and their mean velocity (represented by the arrows). The significance 
of measuring flux is depicted in the represented examples: vesicles traveling at the same mean velocity, but with 
different mean sizes, or in different numbers, generate distinct fluxes (axons A and B); or, vesicles traveling at 
different mean velocities and with different mean sizes may still give rise to identical fluxes (axons A and C). (F) 
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Axonal flux ([intensity] μm-1 s-1) of vesicles loaded with each nanoparticle type, normalized to the TMCSHROX 
flux value, and represented as mean ± standard error of the mean. 
 ***p < 0.001. 






Figure 6. Mitochondria axonal transport characterization after nanoparticle treatment. (A) Characterization of 
mitochondria motility (%) as paused/stationary or moving. (B) Average velocity (μm/s) of moving mitochondria. 
Values represent mean ± SD. 
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Figure 7. Impact of nanoparticle treatment in neuronal metabolic activity. (A & B) Metabolic activity of DRG 
neurons after nanoparticle administration to the axonal terminals (microfluidic chambers) versus to the whole 
cells (96-wells plate, conventional cultures). (C & D) Metabolic activity of DRG neurons cultured in microfluidic 
chambers after nanoparticle administration to the axonal terminals or cell body. Cellular ATP levels were 
measured after incubation with nanoparticles vehicle (control), TMCSH or TMCSHHC nanoparticles for 6 (A & C) 
or 12 h (B & D). The ATP levels are expressed as a percentage of control cultures. Mean ± SD; n = 3 per condition. 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
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• Nanoparticles have opened new exciting avenues for the development of therapeutic strategies for nervous 
system diseases. Consequently, the search for neuron-targeted nanoparticles as specific delivery vectors of 
therapeutic agents has increased, as well as efficient minimally invasive peripheral routes of administration.  
• The currently available in vitro platforms and in vivo models to test nanoparticles in the framework of the 
nervous system have shown limitations. 
Methods 
• Compartmentalized dorsal root ganglia neuron cultures were established using microfluidic devices. 
• Neuron-targeted and nontargeted nanoparticles based on thiolated trimethyl chitosan were prepared and 
incubated with neuron axonal terminals in the axonal compartment of microfluidic-based neuron cultures.  
• The explored nanoparticle-targeting moiety was the nontoxic carboxylic terminal fragment from the tetanus 
neurotoxin (HC). 
• Nanoparticle bio-performance was evaluated by real-time visualization and quantification of the axonal 
transport of nanoparticle-loaded vesicles, as well as by neuronal metabolic activity analysis. 
Results & discussion 
• Both nanoparticles were internalized at axon terminals and retrogradely transported to cell bodies at similar 
average velocities. 
• Neuron-targeted nanoparticles showed a 2.7-times higher axonal flux than nontargeted nanoparticles, 
suggesting an improvement in cargo transportation efficiency to the cell bodies. 
• Peripheral administration of nanoparticles to axon terminals is nontoxic as compared with their direct 
administration to the whole neuron (cell body and axons), the approach used in the conventional in vitro neuron 
cultures to test nanoparticles cytotoxic effect. 
Conclusion 
• The application of this microfluidic-based platform provided experimental evidence for the retrograde axonal 
transport and safety of the thiolated trimethyl chitosan-HC nanoparticles. 
• This microfluidic-based neuron culture showed to be of added value in the evaluation of cell–nanoparticle 
interactions, nanoparticle axonal transport and safety, allowing for their rapid translation to subsequent in vivo 
studies. 
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